Post-traumatic stress disorder moderates the association between BrainAge acceleration and GrimAge acceleration.

Neurobiol AgingMay 29, 2026 (epub)
Clinical ResearchPsychiatryOpen access

Jenna Beakas, Alexandra K Dwulit, Ahmed Hussain et al.

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis investigated the role of post-traumatic stress disorder (PTSD) in moderating the relationship between epigenetic aging (GrimAge) and brain aging in 312 individuals, including 174 with PTSD. The study found that lifetime PTSD significantly moderated the association between GrimAge acceleration and both DNA methylation-based and MRI-based BrainAge acceleration, with a standardized mean difference of 0.84.

Key findings

  • Lifetime PTSD moderated the association between PC GrimAge acceleration and DNAm-based BrainAge acceleration (SMD = 0.84, p = 0.01).
  • PTSD moderated the association between GrimAge acceleration and MRI-based BrainAge acceleration (SMD = -0.40, p = 0.02).
  • EAA measures were intercorrelated (0.43 < r meta < 0.84), but MRI-based BrainAge acceleration was not correlated with any EAA estimate (r meta = 0.03, p = 0.56).

Why it matters

Understanding the interaction between PTSD and biological aging can inform clinicians about the heightened risk of age-related comorbidities in PTSD patients, potentially guiding preventive strategies and personalized care.

Source

PubMed · PMID 42235098Free full text on PubMed Central

Published in Neurobiol Aging. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.